EGSB led Lunaphore Technologies SA's Series D1 round.

Founded in 2014, the start-up from the EPFL environment developed an innovative tissue diagnosis system based on award-winning, proprietary and high-precision microfluidic technology. The groundbreaking chip technology in terms of fluidics enables the rapid and precise extraction of spatial proteome and genome data, e.g. from tumors. With the perspective of turning every tissue sample into a spatial multiplex analysis, Lunaphore enables researchers in immunology, immuno-oncology, and neuroscience to expand the frontiers of scientific discovery and drug development.

“We are delighted to have such a reputable name as EGSB among our investors. EGSB has an excellent track record of helping fast-growing companies. In addition, the Norgine Ventures credit facility will help us scale our business even faster,” said Ata Tuna Ciftlik, CEO of Lunaphore. “The financing round comes at an important time, as the recently launched COMET™ product line is enjoying extremely strong demand. We are proud that the world's best institutions and blue chip pharmaceutical companies are among our customers.”

“Cutting-edge technology for the next level of biology and medicine — that is Lunaphore,” says Dominik Sauter, managing director of EGS Beteiligungen AG, summarizing the investment. “Lunaphore is at a turning point in its development, and we are pleased to support the leadership team led by CEO Ata Tuna Ciftlik in implementing their vision,” adds Dominik Sauter.

Lunaphore is headquartered in Tolochenaz (Kt. Waadt) and employs around 120 people worldwide.